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Abstract Prescription opioids have increasingly been in-
volved in overdose deaths and treatment admissions. Dis-
posal programs may play an important role in curbing this
trend. The objectives of this study were to: (1) quantify the
prescription opioids returned for disposal to a local take-
back program, and (2) explore selected drug characteristics
that may predict the quantity of unused opioids. Leftover
prescription opioid medications returned for disposal to a
community drug take-back event were quantified and ana-
lyzed according to controlled substances schedule, formu-
lation, number of active ingredients, and directions for use.
Days’ supply of medication remaining, calculated using the
number of dosage units remaining divided by the maximum
number of dosage units per day allowed by the prescriber,
was the primary outcome variable. Opioid prescriptions
returned for disposal had greater than 60 % of the amount
dispensed remaining unused. Short-acting C-II and C-III
combination opioids accounted for greater than 80 % of the
prescriptions returned. Day supply dispensed was the
strongest predictor of day supply remaining, regardless of
other drug characteristics. These findings indicate that dis-
posal programs are effective at removing unused medication
from patient homes. To reduce leftover medication, pre-
scriber education programs should address the amount to be
prescribed. Continual monitoring of quantities prescribed
and returned for disposal may be useful in evaluating the
effects of these programs on leftover medication. Further
research on drug characteristics may inform prescribing
practices and reduce leftover medication.
Key Points
Opioid prescriptions returned for disposal had
[60 % of the amount dispensed remaining unused.
Day supply dispensed was the strongest predictor of
day supply remaining.
1 Introduction
Nonmedical use (abuse, misuse, and addiction) of pre-
scription opioids results in serious public health conse-
quences as evidenced by increased opioid-related treatment
admissions [15] and escalating mortality [6]. In 2007,
poisoning became the second leading cause of accidental
death in the USA [4]. This trend is largely attributed to
prescription opioid overdose, which has increased threefold
since 1999 [20]. Admissions for treatment of prescription
opioid abuse increased fivefold (from 1 to 5 %) between
1997 and 2007 [18], and an additional 16 % between 2008
and 2009 [19]. Furthermore, survey and risk assessment
data indicate that friends and relatives are the primary
sources of nonmedically used opioids [5, 12, 17],
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highlighting the importance of understanding and reducing
the volume of leftover prescription opioids that are avail-
able for nonmedical use.
Multiple federal agencies have recognized the impor-
tance of reducing prescription drug abuse, misuse, and ad-
diction. The Office of National Drug Control Policy’s
(ONDCP) 2011 Prescription Drug Abuse Prevention Plan
(the Plan) [14] focused on prescription opioids as a drug
class due to both the increase in the number of opioid pre-
scriptions filled annually in the USA and trends in pre-
scription opioid overdose deaths. The Plan identified
multiple strategies for reducing morbidity and mortality
associated with nonmedical opioid use, including: (1)
education of patients, youths and their parents, and health-
care practitioners, primarily through risk evaluation and
mitigation strategies (REMS), (2) tracking and monitoring
through state-authorized prescription drug monitoring pro-
grams (PDMPs), and (3) enforcement against diversion-re-
lated activities such as ‘‘doctor shopping’’ and ‘‘pill mills’’.
The final major strategy identified in the Plan was dis-
posal of leftover medications as a way to reduce the vol-
ume of medication available for illicit use. ‘‘Take-back’’
programs are one mechanism for legally collecting un-
wanted and expired medications from households for dis-
posal. These programs are still relatively new phenomena
in the USA, and began as local efforts with the state and
federal governments merely enforcing existing hazardous
waste or transportation regulations [9]. The federal gov-
ernment’s growing recognition of the importance of col-
lection and disposal of unwanted medications is further
evidenced in the Environmental Protection Agency’s mail-
back program [9] and the passing of the Secure and Re-
sponsible Drug Disposal Act of 2010, which led to changes
in the Drug Enforcement Administration’s rules and
regulations. The new regulations, effective 9 October 2014,
now allow take-back programs to accept controlled sub-
stances for the purpose of disposal [8].
Take-back programs can offer a unique window for
learning about leftover medications, which remain in
households and are available for potential misuse. The ul-
timate fate of all prescriptions written and dispensed is
completely unknown, given that patients may consume all,
some, or none of a medication. Examining prescriptions
collected through take-back programs allows researchers to
identify, quantify, and explore factors associated with
medications that have been prescribed and dispensed but
that remain unconsumed by patients. Such understanding
can assist in identifying areas of need and strategies for
interventions aimed at reducing availability of unused pre-
scription medications.
This study aims to (1) quantify the prescription opioids
returned for disposal to a local take-back program, and (2)
explore selected drug characteristics that may predict the
quantity of unused opioids. The overarching goal of this
study is informing initiatives of public and private orga-
nizations regarding opioid-related policies and practices.
2 Methods
2.1 Data Collection
Data were collected during a 4-h medication take-back
event known as MedDropTM in Dane County, WI, USA. At
the time, MedDropTM was a series of biannual collection
events, held as a drive-through service where volunteers
collected unwanted medications for disposal from drivers,
who represented households.
At the event, 761 households returned over 1500 lbs
(680 kg) of medications for disposal. Controlled substances
comprised 160 lbs (72.5 kg; 10.7 %) of the total returned,
which filled 30 gallons (113.5 L). The weight and volume
reported includes only medication and as little packaging
as possible. Of the controlled substances, 818 prescriptions
were for opioid pain medications. Of these, 151 prescrip-
tions were visually identified by pharmacists as opioids, but
were missing prescription labels, and were excluded from
data collection. Fifty-seven prescriptions were excluded
because they are listed by the DEA as Schedule IV (C-IV)
prescriptions (propoxyphene-containing products [n = 49],
tramadol [n = 8]). Five prescriptions were excluded be-
cause they are used for conditions other than generalized
pain (butorphanol [n = 1], hydrocodone/guaifenasin or
codeine/guaifenasin [n = 4]). This study focuses on the
remaining 605 Schedule II (C-II) and Schedule III (C-III)
opioid prescriptions returned for disposal.
Data were recorded by trained pharmacy students. Items
of information recorded from labels were: drug name and
strength; date dispensed; brand name or generic product;
directions for use; quantity dispensed; and quantity re-
maining (determined by counting the number of dosage
units in the returned prescription bottle).
To protect privacy, all households were advised to re-
move or darken protected health information (PHI) from
prescription labels prior to returning prescriptions for dis-
posal. Volunteers were also required to sign a confiden-
tiality agreement, should any PHI remain visible. The
University of Wisconsin-Madison Social and Behavioral
Sciences Institutional Review Board exempted this study
from review.
2.2 Variables
Days’ supply of a medication is a measure commonly used
by pharmacists and insurers to determine the length of time
a prescription should last before the medication is used up
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and/or a refill is issued [2, 8, 10, 11, 21]. Days’ supply of
medications accounts for more information regarding how
a medication was used than other measures of medications
remaining. It is based on the amount of a medication that a
patient has been prescribed to safely take each day and is
calculated as:
Days’ supply ¼ Number of dosage units availableð Þ=
Maximum number of dosage units consumed in one dayð Þ
Days’ supply remaining was the outcome variable of
interest. It was calculated using the number of dosage units
remaining, that is, the amount of unused medication
returned in the take-back event.
Days’ supply dispensed was used as a predictor variable
for the days’ supply remaining, as larger amounts pre-
scribed (and thus dispensed) permit larger amounts to re-
main. Days’ supply dispensed was calculated using the
number of dosage units originally dispensed, as opposed to
the number of dosage units remaining.
Effects of three medication characteristics on the amount
of medication returned were explored: combination, formu-
lation, and directions for use. Each returned prescription was
identified by its drug name and DEA schedule (i.e., C-II or
C-III). Each drug then was categorized by active ingredi-
ent(s) (0 = combination, 1 = single-entity) and formulation
(0 = short-acting, 1 = long-acting/extended-release). Long-
acting and extended-release products included various for-
mulations that deliver a short-acting opioid in a delayed
manner and methadone, which exhibits a long half-life and
duration of action. From the prescription label, directions for
use were identified as either on a scheduled or ‘‘as needed’’
(PRN) basis (0 = as needed, 1 = scheduled).
2.3 Data Analysis
Statistical analysis was conducted using SPSS (v. 19, IBM
Corporation, Somers, NY, USA). Descriptive statistics
were calculated for the number of dosage units remaining
and dispensed, the days’ supply remaining and dispensed,
and the percent remaining.
Linear regression was used to identify predictors of
days’ supply remaining. Three models were constructed for
C-II prescriptions; each included days’ supply dispensed
and one of the three medication characteristics. Models
were constructed in this way due to multicollinearity of the
three variables used to characterize the medications. The
single model constructed for C-III prescriptions included
only days’ supply dispensed and whether the medication
was prescribed in a scheduled or PRN basis. All returned
prescriptions that contained C-III medications were short-
acting, combination products; therefore, formulation and
active ingredient variables could not be analyzed.
In examining the data, 12 prescriptions were identified as
having a days’ supply remaining greater than the days’
supply dispensed (i.e., a negative difference in days’ sup-
ply). These prescriptions did not follow the logical as-
sumption that the medications returned for disposal were
the medications dispensed originally, and were excluded
from the regression analysis. The data did not follow a
normal distribution; however, two sensitivity analyses were
run to corroborate the conclusions reached with the results
of the models run in this study. Assumptions of linear re-
gression were tested using variance inflation factor (VIF),
Durbin–Watson test for autocorrelation, and visual inspec-
tion of residuals. A weighted least squares model was run to
adjust for heteroscedasticity; but no benefit was found for
this model compared to the ordinary least squares model.
3 Results
As noted in the methods, this study describes 605 pre-
scriptions for opioid pain medications. These 605 pre-
scriptions represented 11 unique opioid pain medications
(Table 1). Of the 11 opioid pain medications identified, nine
were C-II controlled substances. They accounted for 37.9 %
of all returned prescriptions and 47.6 % of all returned





All C-II 229 (37.9) 6763.5 (46.7)
Fentanyl transdermalc 21 (3.5) 133 (0.9)
Hydromorphone 1 (0.2) 60 (0.4)
Meperidine (pethidine) 1 (0.2) 4 (0.0)
Methadonec 10 (1.7) 422 (2.9)
Morphine 12 (2.0) 571 (3.9)
Morphine SRc 10 (1.7) 273 (1.9)
Oxycodone 26 (4.3) 1254 (8.7)
Oxycodone ERc 25 (4.1) 1117 (7.7)
Oxycodone/APAP or /ASA 123 (20.3) 2929.5 (20.2)
All C-III 376 (62.1) 7713.5 (53.3)
Codeine/APAP 103 (17.0) 1978.5 (13.7)
Hydrocodone/APAP 273 (45.1) 5735 (39.6)
Total 605 (100) 14,477 (100)
C-II (Schedule II) and C-III (Schedule III) refer to the controlled
substance schedule designated by the Drug Enforcement
Administration
APAP acetaminophen, ASA aspirin
a Combination products were designated by two drug entities
separated by ‘‘/’’ (e.g., oxycodone/APAP)
b 0.5 dosage unit was recorded for any solid dosage form that was
split in half and for 2.5 mL of a liquid dosage form
c A long-acting (methadone) or sustained- and extended-release
product
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dosage units. C-IIs included short- and long-acting/ex-
tended-release formulations, as well as single-entity and
combination products. Notably, all C-II combination
products were oxycodone-containing products, and ac-
counted for 20 % of all returned prescriptions. The re-
maining two opioid pain medications identified in the
sample were C-III controlled substances; both were short-
acting, combination products. In contrast to the C-II prod-
ucts, however, these two C-III products accounted for the
majority of analyzed prescriptions (62.1 %) and aggregate
number of dosage units (53.3 %) returned for disposal.
When C-II and C-III medications are compared
(Table 2), results showed that C-IIs were dispensed and
returned with a greater number of dosage units
(56.6 ± 60.5 vs. 31.7 ± 22.4, p\ 0.001; 29.5 ± 37.8 vs.
20.5 ± 17.9, p\ 0.001, respectively) and were dispensed
and returned with a larger days’ supply (14.5 ± 18.3 vs.
4.3 ± 4.8, p\ 0.001; 7.3 ± 8.8 vs. 2.7 ± 3.7, p\ 0.001,
respectively). C-II medications were returned with a
smaller percentage of dosage units remaining when com-
pared with C-IIIs (58.1 % ± 33.1 vs. 65.7 % ± 30.4,
p = 0.004). The difference between the days’ supply dis-
pensed and the days’ supply remaining represents the days’
supply used by the patient prior to disposal. In this sample,
patients used a 7-day supply of C-II prescriptions, and a
1.5-day supply of C-III medications.
3.1 Drug Characteristics
Four long-acting/extended-release products were included
in the returned medications; they accounted for ap-
proximately 11 % of all prescriptions and all dosage units
returned for disposal (Table 1). Analysis of dosage units
and days’ supply (Fig. 1) showed that smaller amounts of
short-acting medications were dispensed and returned for
disposal compared with long-acting/extended-release
products. In this sample, patients used a 2.5 days’ supply of
short-acting medications versus a 14 days’ supply of long-
acting/extended-release products. Short-acting medications
were returned for disposal with a significantly larger per-
centage of the dispensed amount remaining, compared with
long-acting/extended-release products (64.2 ± 31.6 % vs.
51.5 ± 29.5 %, p = 0.002, not shown in figure).
Three combination products, containing hydrocodone,
oxycodone and codeine, accounted for 82.4 % of the pre-
scriptions and 73.5 %of the dosage units returned for disposal
(Table 1). Smaller amounts of combinationmedications were
dispensed and returned for disposal when compared with
single-entity products (Fig. 1). Combination products were
returned with a larger percentage of the dispensed amount
remaining compared with single-entity products; however,
this difference was not statistically significant.
Medications prescribed to be taken ‘‘as needed’’ were
dispensed and returned with a smaller number of dosage
units and days’ supply, when compared with medications
prescribed to be taken on a schedule. However, ‘‘as need-
ed’’ prescriptions were returned with a greater percent of
medication remaining compared with those taken on a
schedule; again, this difference was not statistically
significant.
3.2 Predictive Factors
In light of the systematic differences observed regarding
the days’ supply of medication dispensed, multivariate
models were constructed to compare how selected











Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
All C-II 56.5 (60.5) 29.5 (37.8) 58.1 % (33.1) 14.5 (18.3) 7.3 (8.8)
Fentanyl transdermalb 11.0 (6.7) 6.3 (4.2) 64.4 % (31.6) 31.8 (20.8) 18.5 (13.1)
Hydromorphone 60.0 N/A 60.0 N/A 100 % N/A 10.0 N/A 10.0 N/A
Meperidine (pethidine) 5.0 N/A 4.0 N/A 80.0 % N/A 0.4 N/A 0.3 N/A
Methadoneb 198.6 (103.1) 42.2 (36.6) 21.3 % (14.8) 25.3 (12.3) 5.4 (4.6)
Morphine 61.8 (51.6) 47.6 (50.3) 71.3 % (21.9) 14.3 (12.1) 8.9 (7.6)
Morphine SRb 53.0 (21.2) 27.3 (15.5) 57.1 % (30.2) 27.9 (9.6) 14.8 (8.2)
Oxycodone 79.2 (66.0) 48.2 (44.1) 68.4 % (40.4) 20.8 (35.7) 9.8 (9.2)
Oxycodone ERb 74.0 (85.4) 44.7 (75.3) 50.6 % (23.8) 23.8 (9.4) 12.2 (8.0)
Oxycodone/APAP or /ASA 44.5 (33.1) 23.8 (22.3) 57.6 % (33.5) 6.6 (9.0) 3.4 (5.2)
All C-III 31.7 (22.4) 20.5 (17.9) 65.7 % (30.4) 4.3 (4.8) 2.7 (3.7)
Codeine/APAP 29.1 (18.4) 19.2 (14.7) 67.8 % (27.1) 3.6 (3.6) 2.4 (2.9)
Hydrocodone/APAP 32.7 (23.7) 21.0 (18.9) 64.9 % (31.5) 4.5 (5.2) 2.8 (3.9)
Total 41.1 (42.9) 23.9 (27.5) 62.8 % (31.6) 8.1 (12.8) 4.4 (6.5)
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medication characteristics predicted the days’ supply of
unused medication returned for disposal. Four models were
analyzed, three for C-II prescriptions and one for C-III
prescriptions (Table 3).
All models showed that days’ supply of medication
dispensed was a strong predictor of days’ supply remain-
ing. An increase of one-day supply dispensed resulted in an
additional quarter- (Model 1; B = 0.229) to half- (Model 4;
B = 0.494) day supply returned for disposal.
Focusing on C-II medications, a greater days’ supply
remaining was predicted by long-acting/extended-release
products, single-entity active ingredients, and directions to
take on a scheduled basis. When compared with short-
acting medications, a 4.7 greater days’ supply of long-
acting medications was predicted to remain for disposal
(Model 1). When compared with combination products, a
4.3 greater days’ supply of single-entity products was
predicted to remain for disposal (Model 2). Finally, when
compared with prescriptions taken on a scheduled basis, a
4.5 greater days’ supply of prescriptions taken ‘‘as needed’’
remained for disposal (Model 3). In contrast to C-II
medications, directions for use was not predictive of the
days’ supply remaining for C-III medications (Model 4).
The study models predicted 43 % (Model 1) to 65 %
(Model 4) of the variability in the days’ supply of
medication returned for disposal. Notably, the strongest
model, which predicts returned C-III medications, was
driven by the days’ supply of medication dispensed.
Sensitivity analyses of both the log transformed out-
come variable and a reconceptualized outcome variable
(the percent of medication remaining) that accounts for the
amount of medication dispensed indicate that the days’
supply dispensed is the strongest predictor of the amount of
medication remaining. The decision to report the results of
the days’ supply remaining models was based on the
clinical relevance and interpretability of the results.
4 Discussion
Three findings of this study are particularly relevant to
prevention of nonmedical use of prescription opioids. First,



















































































Fig. 1 Comparisons of drug characteristics. a Dosage units dispensed. b Dosage units remaining. c Days supply dispensed. d Days supply
remaining
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opioid prescriptions returned for disposal had greater than
60 % of the amount dispensed remaining unused. Second,
drug utilization differed by drug characteristics. Notably,
short-acting C-II and C-III combination opioids accounted
for greater than 80 % of the prescriptions returned for
disposal. And finally, the day supply dispensed was the
strongest predictor of day supply remaining, regardless of
other drug characteristics.
Of the strategies laid out in the ONDCP’s Plan, the
findings of this study are most relevant to education and
disposal. Prescriber education, through continuing educa-
tion, school curricula and resources such as REMS, should
emphasize the importance of the quantity of medication
prescribed and subsequently dispensed. Quantities pre-
scribed should reflect the clinical need of the patient [1].
Similarly, prescriber education should acknowledge
differences in use based on drug characteristics. For ex-
ample, patients used a 2-week supply of long-acting/ex-
tended-release medications versus a 2.5-days’ supply of
short-acting medications. Notably, short-acting medica-
tions, particularly hydrocodone- and oxycodone-containing
products, constituted a large proportion of the prescriptions
returned for disposal. As such, prescriber education should
encompass both short- and long-acting opioid-containing
products and their uses in acute and chronic pain.
This study showed that including data collection as a
component of disposal programs offers a unique perspec-
tive on unused prescription medication. ONDCP recog-
nized disposal programs as important in reducing diversion
of prescription opioids. However, few published studies
have evaluated the effect of disposal programs. Data from a
disposal program that includes quantities dispensed and
returned provides insight into a largely unknown con-
tributor to diversion. These findings can shed light on ac-
tual usage patterns and identify areas warranting future
study.
Data from take-back programs can also be used to
monitor the effects of other initiatives aimed at reducing
nonmedical use of prescription opioids. Longitudinally,
these data reveal trends in amounts of leftover medication
and utilization. Similarly, they may augment efforts to
evaluate the effects of policy changes, such as the reclas-
sification of hydrocodone as a C-II [16], which went into
effect on 6 October 2014. Longitudinal studies could po-
tentially show changes in the utilization of hydrocodone
products returned for disposal before and after the policy
change. It would be interesting to see how prescriptions for
other medications change as well. ONDCP’s support of
disposal programs should include a plan for collecting data
from disposal programs as indicators for diversion potential
and evaluating effects of disposal programs.
Like all studies, this study has limitations. First, patients
dropping off medication for disposal are self-selecting and
may not reflect the general population. Second, it is pos-
sible a portion of the returned medication was diverted
prior to collection for disposal, resulting in an overesti-
mation of the amount of medication used by the patient for
medical purposes. However, it is safe to say that of the
returned prescriptions the amount of medication used was
less than the amount prescribed. Third, findings of this
study are limited by geographical region and cross-sec-
tional design. Multiple studies by the Centers for Disease
Table 3 Regression results
predicting days’ supply
remaining
a Formulation: 0 = short-
acting, 1 = long-acting/
extended-release
b Active-ingredients:
0 = combination, 1 = single-
entity
c Directions for use: 0 = ‘‘as
needed’’, 1 = scheduled
B 95 % CI p b VIF
C-II medications
Model 1
Formulationa 4.703 2.547–6.859 \0.001 0.245 1.246
Days’ supply dispensed 0.244 0.190–0.297 \0.001 0.512
R2 = 0.434 (df = 219)
Model 2
Active ingredientsb 4.286 2.269–6.303 \0.001 0.244 1.292
Days’ supply dispensed 0.240 0.186–0.295 \0.001 0.505
R2 = 0.431 (df = 219)
Model 3
Directions for usec 4.502 2.398–6.607 \0.001 0.257 1.417
Days’ supply dispensed 0.229 0.172–0.26 \0.001 0.482
R2 = 0.432 (df = 219)
C–III medications
Model 4
Directions for usec -0.024 -0.561–0.513 0.93 -0.003 1.015
Days’ supply dispensed 0.494 0.456–0.532 \0.001 0.804
R2 = 0.646 (df = 362)
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Control and Prevention (CDC) and NCDI have recognized
regional differences in prescription opioid abuse and mis-
use [3, 6, 12, 13]. This study should be replicated in other
regions and conducted longitudinally to identify patterns
across geography and time, respectively. Finally, the
medication characteristics were limited to the information
present on the medication bottle at disposal. Future studies
should include additional factors that may further charac-
terize the patients and prescribers associated with unused
medication.
In summary, we found the days’ supply of medication
dispensed to be the strongest predictor of the days’ supply
of medication remaining for disposal. Prescribers should
consider this while writing prescriptions for opioids of any
kind—C-II or C-III, long- or short-acting, combination or
single entity. Further investigation of different drug char-
acteristics may inform prescribing practices and reduce
leftover prescription opioid medication.
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